TICKERNOMICS Sign up
Last Update: 2023-12-23 05:57:20
AbbVie Inc. ( ABBV ) https://www.abbvie.com
152.59USD
Sector:
Healthcare
Industry:
Drug Manufacturers-General
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-2.64%
ABBV
SPY
30.72%
ABBV
78.52%
SPY
112.82%
ABBV
170.62%
SPY
201.04%
ABBV
549.14%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
270236.89
336447.89
4.04
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
41.49
4.90
20.95
10.75
4.06
15.42
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
16.38
53.44
39.57
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
5.8886
9.14
10.74
0.49
Other Earnings and Cash Flow Stats:
AbbVie Inc. ( ABBV ) Net Income TTM ($MM) is 8439.00
AbbVie Inc. ( ABBV ) Operating Income TTM ($MM) is 15154.00
AbbVie Inc. ( ABBV ) Owners' Earnings Annual ($MM) is 24954.68
AbbVie Inc. ( ABBV ) Current Price to Owners' Earnings ratio is 11.51
AbbVie Inc. ( ABBV ) EBITDA TTM ($MM) is 21852.00
AbbVie Inc. ( ABBV ) EBITDA Margin is 39.57%
Capital Allocation:
AbbVie Inc. ( ABBV ) has paid 6.20 dividends per share and bought back 5.0 million shares in the past 12 months
AbbVie Inc. ( ABBV ) has reduced its debt by 12595.0 million USD in the last 12 months
Capital Structure:
AbbVie Inc. ( ABBV ) Interest-bearing Debt ($MM) as of last quarter is 66218
AbbVie Inc. ( ABBV ) Annual Working Capital Investments ($MM) are -6857
AbbVie Inc. ( ABBV ) Book Value ($MM) as of last quarter is 12898
AbbVie Inc. ( ABBV ) Debt/Capital as of last quarter is 514%
Other Balance Sheet Stats:
AbbVie Inc. ( ABBV ) has 13287 million in cash on hand as of last quarter
AbbVie Inc. ( ABBV ) has 34773 million of liabilities due within 12 months, and long term debt 61015 as of last quarter
AbbVie Inc. ( ABBV ) has 1771 common shares outstanding as of last quarter
AbbVie Inc. ( ABBV ) has 0 million USD of preferred stock value
Academic Scores:
AbbVie Inc. ( ABBV ) Altman Z-Score is 2.09 as of last quarter
AbbVie Inc. ( ABBV ) Piotroski Score is 7.00 as of last quarter
Corporate Governance:
AbbVie Inc. ( ABBV ) largest shareholder is UBS Asset Mgmt Americas Inc owning 9983369 shares at 1523.36 ($MM) value
Josh Gottheimer(an insider) Sold 0 shares of AbbVie Inc. ( ABBV ) for the amount of $0.00 on 2023-11-08
0.13% of AbbVie Inc. ( ABBV ) is held by insiders, and 71.41% is held by institutions
AbbVie Inc. ( ABBV ) went public on 2013-01-02
Other AbbVie Inc. ( ABBV ) financial metrics:
FCF:25643.00
Unlevered Free Cash Flow:-6246.00
EPS:4.02
Operating Margin:16.38
Gross Profit Margin:53.44
Div. Payout Ratio%:168.56
Div. Growth YoY%:9.93
Equity Return%:58.81
Beta:0.49
Buffet's Owners Earnings:24954.68
Price to Owner's Earnings:11.51
About AbbVie Inc. ( ABBV ) :
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh├žet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.